Sanofi reported €762m of net income in the second quarter 2018, after net sales of €8,176 million, down 5.7% on a reported basis.
Chief Executive Officer, Olivier Brandicourt, said that the company reached several important milestones in building its new Rare Blood Disorder franchise and the successful continued execution of the global roll-out of Dupixent, and that, as the impact from the U.S. losses of exclusivity peaked in the second quarter, the growth of Sanofi’s diversified businesses largely compensated for these headwinds.